Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 12;56(5):2001154.
doi: 10.1183/13993003.01154-2020. Print 2020 Nov.

High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU

Tiphaine Guy  1   2 , Audrey Créac'hcadec  1   2 , Charles Ricordel  3   4 , Alexandre Salé  3 , Baptiste Arnouat  1 , Jean-Louis Bizec  1 , Marie Langelot  1 , Christine Lineau  1 , David Marquette  1 , Françoise Martin  1 , Mathieu Lederlin  5   6 , Stéphane Jouneau  7   8
Affiliations

High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU

Tiphaine Guy et al. Eur Respir J. .

Abstract

SARS-CoV-2 infected patients with nonhypercapnic acute hypoxaemic respiratory failure can benefit from high-flow nasal oxygen outside an ICU. The technique appears to be safe for healthcare workers and could well liberate critical ICU resources. https://bit.ly/2Xq80iu

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T. Guy has nothing to disclose. Conflict of interest: A. Créac'hcadec has nothing to disclose. Conflict of interest: C. Ricordel has nothing to disclose. Conflict of interest: A. Salé has nothing to disclose. Conflict of interest: B. Arnouat has nothing to disclose. Conflict of interest: J-L. Bizec has nothing to disclose. Conflict of interest: M. Langelot has nothing to disclose. Conflict of interest: C. Lineau has nothing to disclose. Conflict of interest: D. Marquette has nothing to disclose. Conflict of interest: F. Martin has nothing to disclose. Conflict of interest: M. Lederlin has nothing to disclose. Conflict of interest: S. Jouneau reports and fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups, research projects over the past 3 years from AIRB, Bellorophon Therapeutics, Biogen, Boehringer, Chiesi, Fibrogen, Galecto Biotech, Genzyme, Gilead, GSK, LVL, Novartis, Olam Pharm, Pfizer, Pliant Therapeutics, Roche, Sanofi and Savara-Serendex.

Figures

FIGURE 1
FIGURE 1
Graphic representation of the 27 coronavirus disease 2019 (COVID-19) patients treated with high-flow nasal oxygen (HFNO) in the pulmonology department of Vannes Hospital, France. Main outcomes are reported, such as intensive care unit (ICU) admission, orotracheal intubation and death.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at... WHO Director-General's Opening Remarks at the Media Briefing on COVID-19 – 18 March 2020.
    1. Grasselli G, Zangrillo A, Zanella A, et al. . Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323: 1574–1581. doi:10.1001/jama.2020.5394 - DOI - PMC - PubMed
    1. Frat JP, Thille AW, Mercat A, et al. . High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372: 2185–2196. doi:10.1056/NEJMoa1503326 - DOI - PubMed
    1. Cheung JC, Ho LT, Cheng JV, et al. . Staff safety during emergency airway management for COVID-19 in Hong Kong. Lancet Respir Med 2020; 8: e19. doi:10.1016/S2213-2600(20)30084-9 - DOI - PMC - PubMed
    1. Alhazzani W, Møller MH, Arabi YM, et al. . Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020; 46: 854–887. doi:10.1007/s00134-020-06022-5 - DOI - PMC - PubMed

LinkOut - more resources